glp-1 obesity drug news today september 29 2025 How Supply and Demand for Weight Loss Drugs is Playing Out in 2026 Lilly hikes revenue forecasts on

The reported physiological alterations were underpinned by the increased mRNA levels of lipid metabolism-related genes ( pparg , fasn ), favouring lipogenesis and lipid accumulation [273]

Aging Cell 23 (2), 14041

Visfatin/PBEF/Nampt: a new cardiovascular target

Most of the available data on the drugs safety come from preclinical investigations

The pharmacokinetics of FOXO4-DRI, including its administration routes, are a focal point of ongoing research, especially in terms of optimizing its delivery and minimizing off-target effects

These two drugs were real gamechangers, as they were very strong competitors to Novo Nordisks Ozempic and Wegovy